SpyGlass Pharma (SGP) highlighted progress on its BIM-IOL intraocular lens—a glaucoma treatment combining a bimatoprost drug-eluting implant with a standard IOL—at the Citigroup Biopharma Back to School Summit. The device is designed to deliver medication for up to three years, addressing a significant unmet need in ophthalmology. With a market of roughly 5 million U.S. cataract procedures annually, about 1 million involve glaucoma patients, a segment growing at 3% year-over-year. Current treatments leave roughly 500,000 procedures underutilized due to insufficient glaucoma management options. SpyGlass’s pipeline is advancing toward a 2029 commercial launch, contingent on Phase III success.
SpyGlass Pharma’s Glaucoma Lens Nears Phase III Milestones with $920M Runway
The biotech firm’s BIM-IOL drug-delivery implant shows promising efficacy in reducing glaucoma medication use, with Wall Street targeting $37–$62 per share.
PA
Priya Anand · Equities & Earnings Desk · 21 Sept 2026 · 04:56 · 1 min read
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
PA
Written by
Priya Anand
Equities & Earnings Desk
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
